Register to attend a free NIH webinar. Attendees will learn about a new T-cell receptor (TCR) that targets CD22, being developed by the National Cancer Institute (NCI) as a cellular immunotherapy to treat lymphomas and leukemias. CD22 TCR-T cells clear leukemia at clinically relevant doses without causing systemic cytokine elevation. The webinar will highlight: Novel CD22 specific TCR-T cells reducing tumor burden at clinically relevant doses A new therapeutic method using these novel CD22 specific TCR-T cells that overcomes current...

Read More Read More